In a recently released analyst research report, J.P. Morgan‘s Biotechnology Equity Research Analyst, Cory Kasimov, just reiterated his bullish buy rating on shares of Epidiolex producer GW Pharmaceuticals Plc (NASDAQ:GWPH) with a reasonable price target.
Cory Kasimov’s new price target of $180.00 USD per share implies a potential upside of approximately 2.67% based on the last traded price of $175.32 USD on the NASDAQ.
Why Analysts Are Bullish on GWPH
Kasimov’s analyst update came just shortly after Cantor Fitzgerald & Co. Managing Director and Senior Biotechnology Analyst, Elemer Piros Ph.D., reiterated his Overweight buy rating on ADRs of GW Pharmaceuticals Plc (NASDAQ:GWPH) with a higher price target of $196.00 USD per share.
Cantor reiterated their Overweight buy rating on GW Pharmaceuticals and raised their 12-month price target to $196.00 USD per share from $193 USD per share following the recently announced sale of Voucher. While the recipient of the PRV was not announced in the press release, GW did fetch a massive $105 million for it.
According to Markets.co, “The company’s shares opened today at $169.43, close to its 52-week high of $182.23.”
Be sure to subscribe to updates here so you never miss an important development.
Get Real-Time Updates from MJobserver.com